Advertisement

Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature

Abstract

Aims and background. To evaluate the long-term outcome of patients with vestibular schwannoma (VS) and neurofibromatosis type 2 (NF2) treated with fractionated stereotactic radiotherapy (FSRT) or stereotactic radiosurgery (SRS).
Patients and methods. Sixteen VS in 14 patients with NF2 were treated with FSRT (n = 14) and SRS (n = 2). Patients with tumor progression and/or progression of clinical symptoms were selected for treatment. For patients treated with FSRT a median total dose of 57.6 Gy was prescribed with a median fractionation of 5 × 1.8 Gy per week. For patients who underwent SRS a median single dose of 17 Gy was prescribed to the 80% isodose.
Results. FSRT and SRS were well tolerated. Local control rate was 94% for a median follow-up time of 131 months; 2- and 5-year progression-free survival were 100%. The probability of maintaining the pretreatment hearing level was 44%. Useful hearing preservation was 33%. Cranial nerve toxicity was moderate. Trigeminal nerve function worsened in 2 patients (12%) and facial nerve function in 3 patients (19%). One patient developed a new tinnitus.
Conclusion. FSRT and SRS are both safe and effective noninvasive and minimally invasive treatment options for patients with VS in the setting of NF2. The long-term local control rates are excellent. Functional hearing preservation is worse in patients with VS and NF2 than in patients with sporadic VS.

Tumori 2014; 100(2): 189 - 194

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1491.16411

Authors

Johanna Wagner, Thomas Welzel, Daniel Habermehl, Jürgen Debus, Stephanie E Combs

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Wagner, Johanna [PubMed] [Google Scholar]
    Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany
  • Welzel, Thomas [PubMed] [Google Scholar]
    Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany
  • Habermehl, Daniel [PubMed] [Google Scholar]
    Department of Radiation Oncology, Technical University Hospital of Munich, Munich, Germany
  • Debus, Jürgen [PubMed] [Google Scholar]
    Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany
  • Combs, Stephanie E [PubMed] [Google Scholar]
    Department of Radiation Oncology, Technical University Hospital of Munich, Munich, Germany

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.